Abstract
BackgroundAdiponectin is an insulin-sensitizing hormone produced by adipocytes. It has been suggested to be involved in endometrial tumorigenesis. Published data have shown inconsistent results for the association between circulating adiponectin levels and endometrial cancer. In this study, we conducted a meta-analysis to evaluate the predictive value of circulating adiponectin levels on the development of endometrial cancer.MethodsPubMed, Embase, ISI web of knowledge, and Cochrane databases were searched for all eligible studies, and the summary relative risk (SRR) was calculated. Additionally, we performed dose-response analysis with eight eligible studies.ResultsA total of 1,955 cases and 3,458 controls from 12 studies were included. The SRR for the ‘highest’ vs ‘lowest’ adiponectin levels indicated high adiponectin level reduced the risk of endometrial cancer [SRR = 0.40, 95% confidence interval (CI), 0.33–0.66]. Results from the subgroup analyses were consistent with the overall analysis. The SRR for each 1 µg/ml increase of adiponectin indicated a 3% reduction in endometrial cancer risk (95% CI: 2%–4%), and a 14% reduction for each increase of 5 µg/ml (95% CI: 9%–19%). No evidence of publication bias was found.ConclusionsThis meta-analysis demonstrates that low level of circulating adiponectin is a risk factor for endometrial cancer.
Highlights
Endometrial cancer is one of the most frequently diagnosed diseases in gynecologic cancers, with an estimated 280,000 new cases per year worldwide [1]
The summary relative risk (SRR) for each 1 μg/ml increase of adiponectin indicated a 3% reduction in endometrial cancer risk, and a 14% reduction for each increase of 5 μg/ml
No evidence of publication bias was found. This meta-analysis demonstrates that low level of circulating adiponectin is a risk factor for endometrial cancer
Summary
Endometrial cancer is one of the most frequently diagnosed diseases in gynecologic cancers, with an estimated 280,000 new cases per year worldwide [1]. Adiponectin is the most abundant adipocyte-derived factor, which is an insulin-sensitizing hormone and suggested to be involved in endometrial tumorigenesis [6]. In some case-control studies, high circulating levels of adiponectin were shown to be associated with a significant decrease in risk of endometrial cancer [11,12,13,14,15,16,17], while other studies showed no significant associations [18,19,20,21]. We conducted a meta-analysis with all eligible studies to assess the association between circulating levels of adiponectin and endometrial cancer risk. Published data have shown inconsistent results for the association between circulating adiponectin levels and endometrial cancer. We conducted a meta-analysis to evaluate the predictive value of circulating adiponectin levels on the development of endometrial cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
